EGFR and neoplasm: Pharmacological modulation of SIRT6 has shown therapeutic promise, with activators such as MDL-800 inhibiting proliferation and enhancing EGFR-TKI efficacy [81], while natural compounds like α-hederin exert anti-tumor effects through SIRT6-dependent glycolytic inhibition [76].